ARRIVENT BIOPHARMA, INC. Research and Development Expense
ARRIVENT BIOPHARMA, INC. (AVBP) reported Research and Development Expense of $42.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- ARRIVENT BIOPHARMA, INC. research and development expense for the quarter ending 2026-06-30 was $42.34M, a 52.74% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. research and development expense for the quarter ending 2026-03-31 was $37.62M, a 38.62% decline year-over-year.
- ARRIVENT BIOPHARMA, INC. research and development expense for the quarter ending 2025-12-31 was $32.17M, a 59.57% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. research and development expense for the quarter ending 2025-09-30 was $32.17M, a 60.13% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. research and development expense for fiscal 2025 was $153.35M, a 94.11% increase from fiscal 2024.
- ARRIVENT BIOPHARMA, INC. research and development expense for fiscal 2024 was $79.00M, a 21.76% increase from fiscal 2023.
- ARRIVENT BIOPHARMA, INC. research and development expense for fiscal 2023 was $64.88M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $42.34M 10-Q · filed 2026-08-12 | $79.96M 10-Q · filed 2026-08-12 | $112.13M derived: sum of 3 quarters · filed 2026-08-12 | $144.30M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $37.62M 10-Q · filed 2026-05-11 | $69.79M derived: sum of 2 quarters · filed 2026-05-11 | $101.96M derived: sum of 3 quarters · filed 2026-05-11 | $129.68M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $32.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $64.34M derived: sum of 2 quarters · filed 2026-03-05 | $92.06M derived: sum of 3 quarters · filed 2026-08-12 | $153.35M 10-K · filed 2026-03-05 |
| 2025-09-30 | $32.17M 10-Q · filed 2025-11-10 | $59.89M derived: sum of 2 quarters · filed 2026-08-12 | $121.18M 10-Q · filed 2025-11-10 | $141.34M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $27.72M 10-Q · filed 2026-08-12 | $89.01M 10-Q · filed 2026-08-12 | $109.17M derived: sum of 3 quarters · filed 2026-08-12 | $129.26M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $61.29M 10-Q · filed 2026-05-11 | $81.45M derived: sum of 2 quarters · filed 2026-05-11 | $101.54M derived: sum of 3 quarters · filed 2026-05-11 | $123.32M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $20.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $40.25M derived: sum of 2 quarters · filed 2026-03-05 | $62.03M derived: sum of 3 quarters · filed 2026-03-05 | $79.00M 10-K · filed 2026-03-05 |
| 2024-09-30 | $20.09M 10-Q · filed 2025-11-10 | $41.87M derived: sum of 2 quarters · filed 2025-11-10 | $58.84M 10-Q · filed 2025-11-10 | $78.85M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $21.78M 10-Q · filed 2025-08-11 | $38.75M 10-Q · filed 2025-08-11 | $58.76M derived: sum of 3 quarters · filed 2025-08-11 | $73.04M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $16.98M 10-Q · filed 2025-05-12 | $36.98M derived: sum of 2 quarters · filed 2025-05-12 | $51.27M derived: sum of 3 quarters · filed 2025-05-12 | $71.62M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $20.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $34.29M derived: sum of 2 quarters · filed 2025-03-03 | $54.65M derived: sum of 3 quarters · filed 2025-03-03 | $64.88M 10-K · filed 2025-03-03 |
| 2023-09-30 | $14.28M 10-Q · filed 2024-11-14 | $34.64M derived: sum of 2 quarters · filed 2024-11-14 | $44.87M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $20.36M 10-Q · filed 2024-08-14 | $30.59M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $10.24M 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |